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Abstract
Background: Chimeric mice with humanized livers represent a promising tool for infections with Plasmodium
falciparum to evaluate novel methods for prevention and treatment of pre-erythrocytic stages. Adequate assess-
ment of hepatic infections is generally compromised by the limited number of human hepatocytes infected by
developing parasites.
Methods: A qPCR-based method has been developed that sensitively and reliably detects P. falciparum liver stage in-
fection of humanized mice and quantitatively expresses the results as the number of parasites per human hepatocyte.
Results: This assay allows for detection of liver stage parasites after challenging humanized mice with infected
mosquito bites or after intravenous injection with sporozoites. The sensitivity of the protocol, which comprises
approximately 25% of the total chimeric liver, allows for the detection of a single infected hepatocyte in the analysed
tissue.
Conclusions: This method allows for the detection and quantification of P. falciparum parasites in chimeric mice
repopulated with human hepatocytes. It will be a useful tool when studying the in vivo therapeutic and/or prophylactic
qualities of novel compounds, small molecules or antibodies directed against the liver stage of P. falciparum infections.
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Background
Plasmodium falciparum is responsible for most of the
estimated 219 million clinical malaria cases that were re-
ported in 2010 [1]. Rodent models for malaria (e.g. Plas-
modium berghei in mice) are used to test possible new
anti-malarial drugs [2] and candidate vaccines [3] before
entering the clinical phase of downstream product devel-
opment [4]. However, significant differences between ro-
dent models and human malaria [5] necessitate the
availability of alternative models to study P. falciparum.
Humanized mouse models have been developed to study
either blood stage or liver stage of malaria. By engrafting
human red blood cells (huRBC) into immunodeficient
mice, a high percentage of huRBC in mouse peripheral
blood can be obtained [6]. Subsequent injection of in-
fected human erythrocytes results in a blood stage infec-
tion that can be maintained for several days and allows
for the in vivo testing of new therapies against blood
stage infection [7,8]. The liver stage of malaria can be
studied in human liver chimeric mice. These models are
based on the ability of immunodeficient mice with a
severe liver disease to accept a graft of human hepato-
cytes and allow these cells to home into the diseased
mouse liver where their expansion leads to high degrees
of repopulation with human hepatocytes. Immune
deficient mice have acquired severe liver disease
through the transgenic overexpression of urokinase-type
plasminogen activator in uPA+/+-SCID mice or a knock-
out of fumarylacetoacetate hydrolase (FAH) in FRG
(Fah−/−Rag2−/−IL2-Rg−/−) mice [9-13]. These humanized
mice can subsequently be infected with P. falciparum
sporozoites [14,15] and full parasite maturation in
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human hepatocytes can be achieved, but emerging
parasites cannot successfully infect murine erythrocytes
[16]. The Center for Vaccinology (CEVAC) has been
successful in producing chimeric uPA+/+-SCID mice
with a high degree of repopulation with human hepato-
cytes to study hepatitis B and C virus (HBV and HCV)
infections [17-20]. Recently, transfer of human hepato-
cytes was started in FRG mice that originate from
Marcus Grompe’s laboratory [10].
Several methods are available to detect parasites in
an infected humanized mouse model. Immune staining
techniques do visualize infected hepatocytes but quanti-
fication and comparison of animals with different
degrees of human hepatocyte repopulation remains diffi-
cult. Moreover, these techniques are labour-intensive
with low throughput and limited sensitivity [15,21].
Alternatively, a successful infection of the chimeric
mouse liver can be directly visualized in vivo after chal-
lenge with a GFP-luciferase transgenic P. falciparum
strain [22]. While enabling parasite detection without
sacrificing the animal, this technique lacks the sensitivity
to visualize early liver stage infection in vivo [23]. The
lower sensitivity necessitates the infection of humanized
mice by intravenous (IV) injection of up to 106 sporozo-
ites, representing an unnaturally high number of para-
sites [22]. Therefore, a highly sensitive qPCR-based
method was improved to detect and quantify hepatic in-
fections of P. falciparum, after IV injection of sporozo-
ites or following natural infection via mosquito bites.
Methods
Generation of humanized mice
Humanized uPA+/+-SCID mice were generated as previ-
ously described [9]. Briefly, within two weeks after birth
cryopreserved primary human hepatocytes (approxi-
mately 106 cells/mouse, purchased from BD Gentest
(Erembodegem, Belgium)) were injected in the spleens
of uPA+/+-SCID mice [24]. Hepatocytes from the same
donor were used to allow comparison between the
different experiments. Between six weeks after trans-
plantation and up to one week before the infection ex-
periment, human albumin levels in mouse plasma were
measured using Human Albumin ELISA Quantitation
kit (Bethyl Laboratories Inc, Montgomery, TX, USA).
Animals with human albumin levels >2 mg/mL were
considered successfully engrafted and used for infection
studies. All procedures were approved by the Animal
Ethics Committee of the Faculty of Medicine and Health
Sciences of the Ghent University.
Parasite challenge
Plasmodium falciparum NF54 infected Anopheles ste-
phensi mosquitoes were reared as described previously
[25] at Radboud University (Nijmegen, Netherlands).
Chimeric mice were infected with sporozoites, either by
mosquito bites or by injection in the retro-orbital venous
plexus. To mimic a natural infection as closely as pos-
sible, humanized mice were exposed for 20 minutes to
bites of 20 P. falciparum-infected mosquitoes that con-
tained each on average 70,000 sporozoites in the salivary
gland. Before exposure to the mosquitoes, abdomen and
chest of the mice were shaven with electric clippers.
Next mice were positioned on a cardboard box contain-
ing 20 infected mosquitoes (one box for each mouse).
Successful blood feeding (mean: 17 mosquitoes) and
sporozoite presence (100%) was confirmed by mosquito
dissection after the challenge experiment [3,26]. To in-
ject a defined number of parasites, sporozoites were ex-
tracted by hand dissection from the salivary glands of
infected mosquitoes killed by ethanol spraying [23].
Mice were anesthetised with 3% isoflurane in 0.5 L/min
100% O2 and 150,000 salivary gland sporozoites in
100 μl RPMI 1640 (GIBCO) were injected in the retro-
orbital venous plexus [27], because the extremely small
diameter of the tail vein of humanized uPA+/+-SCID
mice precludes intravenous injection.
Isolation of DNA and quantitation of plasmodium
falciparum and human hepatocyte DNA
Five days after infection mice were maximally bled
(around 500 μL) and subsequently euthanized by cer-
vical dislocation. The livers were carefully removed, cut
into 12 standardized sections and stored in RNALater
(Ambion) at 4°C until analysis (Figure 1). Of each sec-
tion, exactly 25 mg (± 0.1 mg) tissue was taken for DNA
extraction in 100 μL elution buffer with the High Pure
PCR Template Preparation Kit (Roche). Plasmodium
falciparum DNA levels were quantified using a highly
sensitive qPCR assay [28]. Briefly, 5 μL DNA extract
was added to 20 μL mastermix (LightCycler 480
Probes Master, Roche) containing P. falciparum
18SRNA gene-specific primers and a probe labelled with
6-carboxy-fluorescein (FAM) as a reporter and 6-
carboxy-tetramethylrhodamine (TAMRA) as a quencher.
Plasmodium falciparum standard curves were prepared
by spiking DNA extracts from titrated samples of ring
stage P. falciparum-infected erythrocytes (range 10–
10,000 parasites (Pf ) per 100 μL extract) with DNA
extracts from a non-infected humanized liver. The de-
tection limit was set at 0.2 Pf/5 μL extract, since the sen-
sitivity of this standardized assay (20Pf/mL blood)
correlates to 0.2 Pf/5 μL extract as shown in Figure 2.
Because the reaction is performed in duplicate it is pos-
sible to detect 0.2 Pf in 10% of the total extract (if only
one out of two reactions is positive). Since all 12 frag-
ments are analysed separately but in an identical way it
is possible to detect two Pf in 300 mg tissue (this if only
one of twelve fragments is positive). To assess the
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repopulation of chimeric livers with human hepatocytes
and to express the P. falciparum infection as a number
of parasites per 106 human hepatocytes, employed a
qPCR was employed as described by Alcoser et al., that
quantifies the relative amount of human and mouse cells
in mixed tissues [29]. Briefly, 1 μL DNA extract was
added to 19 μL mastermix (LightCycler 480 Probes
Master, Roche) containing common primers that amplify
a 215 bp region located in the human and mouse prosta-
glandin E receptor 2 (PTGER2) genes (Figure 3). The
amplified region contains a non-homologous sequence
which is targeted by two species-specific Taqman probes,
each conjugated with a unique fluorescent tag (FAM and
Cy5), which makes it possible to quantify the copy num-
ber and differentiate between mouse and human origin
in duplex. Standard curves were prepared by DNA
extraction from a titration of defined numbers of human
PBMC and mouse splenocytes (Figure 2). Percentage
calculation was verified by making various ratios of
mouse and human DNA extracts.
Liver tissue specimens and histochemistry
Liver samples were fixed in formalin and slides were
stained with haematoxylin-eosin following standard
techniques as described [9].
Results
Standardizing the sampling of humanized liver fragments
Injection of P. falciparum sporozoites in a chimeric
mouse will result in infection of an unknown and low
number of infected human hepatocytes distributed in a
large background of non-infected mouse and human
cells (Figure 4). Consequently, an analysis of the
complete liver by cell lysis and subsequent DNA extrac-
tion will result in a strong dilution of parasitic DNA and
loss of sensitivity. Therefore, exactly 25 mg of liver tissue
was sampled from 12 standardized sections (Figure 1) for
DNA extraction in a volume of 100 μL. Five μL of each
extract was used in duplicate to measure the number of
parasites by qPCR and 1 μL to determine the fraction
(percentage) of human hepatocytes in each fragment
(Figure 2). This approach allowed for the analysis of sev-
eral millions of human hepatocytes randomly distributed
in each chimeric liver (Additional file 1: Table S1).
Measurement of parasites in humanized livers:
standardization and quantification
Both presence of parasite [28] as well as mouse and hu-
man [29] DNA was determined in each fragment by
qPCR (Figures 2 and 3). Since hepatocytes are frequently
multinucleated [30], a histological examination was per-
formed of humanized liver sections of two chimeric
mice as described before [12,31]. Because less than 10%
of both human and mouse hepatocytes displayed a mul-
tinucleated aspect (Figure 4), the calculation of the num-
ber of hepatocytes was not corrected. The ratio of
human DNA versus [human DNA +mouse DNA] was
multiplied by 1.7 because it is described [13,32] that only
60% of chimeric liver tissue consists of hepatocytes (40%
are other cell types) (Additional file 1: Table S1). Calcu-
lating the percentage of human hepatocytes in the
chimeric liver by using the qPCR data made it possible
to compare the degree of repopulation by human hepa-
tocytes of each liver fragment and each liver as a whole.
The degree of repopulation measured in the separate
fragments corresponds well with the average degree
Figure 1 Standardizing the sampling of humanized liver fragments. Five days post-infection, mice are euthanized by cervical dislocation.
The livers are carefully removed, rinsed in PBS and 12 standardized fragments (A-L) are prepared and placed in RNALater until further analysis.
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Figure 3 Species specificity of primers used for the detection of human and mouse DNA. H: human-specific forward primer, contains the
FAM-probe binding site; M: mouse-specific forward primer, contains the Cy5-binding site; H +M: human and mouse common forward primer,
used in qPCR experiments. A human and mouse common reverse primer was used in all reactions. Human PBMC’s and SCID mouse liver extract
give rise to the human and mouse specific PCR products. The human cell line Huh7.5 does not lead to a human or mouse specific PCR product.
Not transplanted mice or low repopulated chimeric mice do not induce a human specific PCR product, whereas a good repopulated chimeric
mouse has both human and mouse specific bands. This confirms that the primers used are specific for the mouse and/or human PTGER2 gene
expressed in a chimeric mouse liver.
Figure 2 Overview of assay procedures. Preparation of liver tissue sections, tissue fragmentation, DNA isolation, qPCR and calculations to
obtain a normalized determination of P. falciparum parasite numbers (left panel) in a humanized liver (right panels).
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(Additional file 1: Table S1). Finally, the liver parasite
burden, expressed as the number of parasites per million
human hepatocytes was calculated by dividing the total
number of parasites detected in the 12 samples derived
from a chimeric liver by the total number of human
hepatocytes in these samples (Figure 2 and Additional
file 1: Table S1).
Comparison of different infection protocols
After the injection of 150,000 P. falciparum sporozoites
in the retro-orbital venous plexus [14,15], infection of
human hepatocytes was demonstrated in all mice (mean:
11,405.6 parasites per 106 human hepatocytes) using the
analytical methods described above (Additional file 2:
Table S2). In addition, humanized mice were exposed
to 20 infected mosquitoes during 20 minutes [33].
Additional file 1: Table S1 shows that the ensuing infec-
tion can be detected in multiple samples (A-L) and is
more comparable in the different animals irrespective of
their degree of chimerism than when mice were chal-
lenged by injection of 150,000 P. falciparum sporozoites
(mean: 1,503.1 parasites per 106 human hepatocytes).
The observed lower variation in the liver parasite burden
was not anticipated since mosquito bites lead to an un-
known and variable parasite challenge [34].
Discussion
A method is presented to detect and quantify P. falcip-
arum parasites in the livers of humanized mice following
infection via intravenous injection of sporozoites or bites
from infected mosquitoes. The approach combines a
systematic analysis of 12 standardized liver sections
from each chimeric liver to avoid sampling bias and
sample dilution with the analytical sensitivities of qPCR
methods to quantify parasite numbers and human hep-
atocyte content of each fragment.
Based on qPCR results obtained by sacrificing human-
ized mice at different time points, it is estimated that a
single infected hepatocyte may contain approximately 20
parasites three days after infection and between 200 and
400 parasites five days after infection. Previous studies es-
timate that this number could rise even further to more
than 30,000 parasites per infected hepatocyte at the end of
the pre-erythrocytic stage, six to seven days after infection
[15,35]. Humanized mice were sacrificed five days after in-
fection because this leaves sufficient time for parasite
DNA not confined to an infected human hepatocyte to be
cleared, while this point in time is sufficiently remote from
the beginning of the end of the liver stage at day 6 to pre-
vent the release of merozoites from infected hepatocytes
and subsequent clearance from the blood since these can-
not infect mouse erythrocytes [15,28].
A
B C
Figure 4 Histology and determination of polyploidy of a chimeric liver. (A) A representative section of a chimeric liver (haematoxylin and
eosin staining) showing the morphological differences between pale human hepatocytes (upper zone), diseased mouse parenchyma (middle
zone) and healthy mouse parenchyma originating from mouse hepatocytes that have eliminated both uPA transgene copies, known as red
nodules (lower zone). Detailed view of chimeric liver sections, showing human hepatocytes (B) none of which is multinucleated and mouse
hepatocytes (C), one of which is binucleated (arrow). Original magnification A: 200 x, B and C: 400 x.
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Analysis of multiple (12) samples from each liver in-
creases the sensitivity of the method as compared to the
analysis of a small sample taken from a homogenized
whole liver. As few as two parasites (Pf) in 300 mg ana-
lysed tissue can be detected. Indeed, the latter approach
may lead to a dilution that is possibly too high to detect
DNA of parasites originating from only a few infected
cells located within a limited zone of the liver. If one as-
sumes that only one human hepatocyte was infected
with P. falciparum, this would result in at least 200 Pf
after five days. Since approximately one quarter of the
total liver was analysed (the liver represents 9% of the
total body weight), there was 25% chance that the in-
fected hepatocyte is located within the tissue analysed.
Since that hepatocyte would be present in one of the 12
fragments, this one fragment would contain at least 200
Pf. Given that the assay has a sensitivity of two parasites
per fragment, the parasites enclosed in a single infected
hepatocyte will be detected. This is considerably better
than any other method currently available for the in vivo
study of Plasmodium falciparum infection (e g, hist-
ology, in vivo bioluminescence with luciferase expressing
parasites, etc.).
Quantification of both human and mouse DNA in
addition to P. falciparum DNA allowed for the deter-
mination of the degree (percentage) of human repopula-
tion of each of the 12 mouse liver fragments (Additional
file 1: Table S1). This approach differs from previous
studies in which the degree of chimerism was calculated
by determining the proportion of the liver parenchyma
surface area that consisted of human hepatocytes based
on immunohistochemical analyses of a series of liver
sections [11,31,36]. Since hepatocytes are much larger
than non-parenchymal cells, the area occupied by
human hepatocytes will overestimate the fraction repre-
sented as cell numbers. The data show that the percent-
age of repopulation of a humanized mouse in different
liver lobes is quite stable and does not significantly
influence the infection with P. falciparum sporozoites
(Additional file 2: Table S2). Figure 5 shows that the
percentage human hepatocytes correlates well with
the human albumin concentrations in chimeric mice
(R = 0.57; P < 0.0001).
Normalizing the liver parasite burden of each animal,
and expressing this as number of parasites per million
human hepatocytes, enables the conduct of comparative
studies while using animals with different degrees of
chimerism. This is important since the generation of
humanized mice is a complex, expensive and time con-
suming process and the resulting chimeric livers have
different degrees of human hepatocyte repopulation.
The data here shows that infected mosquito bites lead
to a detectable infection in chimeric mice that is at least
as reproducible as IV injection of 150,000 sporozoites
isolated from salivary glands of infected mosquitoes
(Additional file 2: Table S2). Using the estimation that
one mosquito blood meal results in the injection of up
to 500 sporozoites [34], exposure to 20 infected mosqui-
toes can possibly result in the deposition of ± 10,000
sporozoites into the skin. This is still 15-fold less than
an IV injection of 150,000 sporozoites and 100-fold less
than the inoculum (106 sporozoites) previously injected
by other investigators [14,15]. The results show that an
IV injection of 150,000 sporozoites leads only to an aver-
age 7.5-fold increase in detected parasites compared to
exposure to 20 infected mosquitoes (Additional file 2:
Table S2). The cause of this discrepancy is not known,
but could be attributed to sporozoites killed during the
dissection process.
Therefore the natural infection route for challenge
may be preferable to study early events during P. falcip-
arum infections for a number of reasons: i) material
injected intravenously also contains an undefined
amount of debris from the dissection of the salivary
glands from the mosquitoes and may compromise suc-
cess of infection and the ensuing processes; ii) IV injec-
tion of sporozoites bypasses a series of natural events
(epithelial crossing, skin cell reactivity, etc.) of which the
precise biological impact and necessity for hepatocyte
recognition and invasion are not yet defined. In this way,
possible effects of tested novel compounds or anti-
sporozoite antibodies will be missed; and, iii) for the
evaluation of agents that may have an effect on sporozo-
ites migration to the liver, the duration of contact prior
Figure 5 correlation human albumin and percentage
repopulation. The calculated percentage repopulation (%huHEP/
totHEP) is plotted against the measured human albumin plasma
concentrations for the animals described in Additional file 2:
Table S2.
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to liver invasion can be of importance. This contact time
is much longer when sporozoites are deposited in the
host’s skin by a mosquito bite (minutes) compared to
direct deposition in the bloodstream [34,37].
Conclusions
A protocol was developed to detect and quantify P.
falciparum parasites to study the therapeutic and/or
prophylactic qualities of novel compounds, small mole-
cules or antibodies, in chimeric mice repopulated with
human hepatocytes. Apart from being susceptible to hu-
man hepatotropic microorganisms these mice also ex-
press a humanized drug metabolism [38-42]. This will
accelerate and reduce the costs of the development of
new strategies to prevent and treat the pre-erythrocytic
stage of malaria before these are tested in human
volunteers.
Additional files
Additional file 1: Table S1. Analysis of the livers of humanized mice
after IV sporozoites injection. Analysis of two infected humanized mice.
Panel 1: number of detected parasites in twelve samples (five μL from
each) and mean. Panel 2: percentage of human hepatocytes in twelve
samples, mean, and percentage repopulation after correction for the
percentage of the liver that is made up of hepatocytes. Panel 3: total
number of human hepatocytes analysed in each sample, total number
human hepatocytes analysed for each mouse, and the liver parasite
burden (expressed as the number of parasites per million human
hepatocytes) calculated from panel 1 and 3.
Additional file 2: Table S2. List of sporozoite injections and mosquito
challenges in humanized mice. Twelve mice were infected by
intravenous sporozoite injection or by mosquito challenge. Panel 1:
human albumin measured by ELISA, percentage repopulation calculated
by qPCR, total number of human hepatocytes analysed per mouse,
number of parasites in twelve samples (five μL from each), mean, and
liver parasite burden (expressed as the number of parasites per million
human hepatocytes). Panel 2: for each infection route or both combined:
mean weight, mean albumin, mean percentage repopulation, mean
number of human hepatocytes analysed, percentage of positive samples
for each sampling site in the humanized livers, mean number of parasites
in each sample (five μL from each), mean liver parasite burden
(expressed as the number of parasites per million human hepatocytes).
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